CN102946871B - 曲马多和昔布类（Coxibs）的共晶体的药物组合物 - Google Patents

曲马多和昔布类（Coxibs）的共晶体的药物组合物 Download PDF

Info

Publication number
CN102946871B
CN102946871B CN201180026578.9A CN201180026578A CN102946871B CN 102946871 B CN102946871 B CN 102946871B CN 201180026578 A CN201180026578 A CN 201180026578A CN 102946871 B CN102946871 B CN 102946871B
Authority
CN
China
Prior art keywords
pharmaceutical composition
pain
composition according
celecoxib
tramadol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180026578.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102946871A (zh
Inventor
兰扎尼 路易斯·佐勒
阿尔迪亚 阿尔贝特·法利韦内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteven Pharmaceutical Co ltd
Esteve Pharmaceuticals SA
Original Assignee
Esteven Pharmaceutical Co ltd
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteven Pharmaceutical Co ltd, Laboratorios del Dr Esteve SA filed Critical Esteven Pharmaceutical Co ltd
Publication of CN102946871A publication Critical patent/CN102946871A/zh
Application granted granted Critical
Publication of CN102946871B publication Critical patent/CN102946871B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201180026578.9A 2010-06-04 2011-06-03 曲马多和昔布类（Coxibs）的共晶体的药物组合物 Active CN102946871B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10384002.1 2010-06-04
EP10384002A EP2392319A1 (en) 2010-06-04 2010-06-04 Pharmaceutical compositions of co-crystals of tramadol and coxibs
PCT/EP2011/002749 WO2011151080A1 (en) 2010-06-04 2011-06-03 Pharmaceutical compositions of co-crystals of tramadol and coxibs

Publications (2)

Publication Number Publication Date
CN102946871A CN102946871A (zh) 2013-02-27
CN102946871B true CN102946871B (zh) 2019-03-08

Family

ID=42358396

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180026578.9A Active CN102946871B (zh) 2010-06-04 2011-06-03 曲马多和昔布类（Coxibs）的共晶体的药物组合物

Country Status (33)

Country Link
US (1) US8846744B2 (enExample)
EP (3) EP2392319A1 (enExample)
JP (1) JP5800016B2 (enExample)
KR (1) KR101556700B1 (enExample)
CN (1) CN102946871B (enExample)
AR (1) AR081774A1 (enExample)
AU (1) AU2011260608B2 (enExample)
CA (1) CA2798090C (enExample)
CO (1) CO6660469A2 (enExample)
CY (1) CY1118813T1 (enExample)
DK (1) DK2575778T3 (enExample)
EC (1) ECSP13012368A (enExample)
ES (1) ES2622192T3 (enExample)
HR (1) HRP20170594T1 (enExample)
HU (1) HUE033999T2 (enExample)
IL (1) IL222731A (enExample)
LT (1) LT2575778T (enExample)
MX (1) MX351507B (enExample)
MY (1) MY156859A (enExample)
NZ (1) NZ603457A (enExample)
PH (1) PH12012502171A1 (enExample)
PL (1) PL2575778T3 (enExample)
PT (1) PT2575778T (enExample)
RS (1) RS55878B1 (enExample)
RU (1) RU2567843C2 (enExample)
SG (1) SG185385A1 (enExample)
SI (1) SI2575778T1 (enExample)
SM (1) SMT201700261T1 (enExample)
TN (1) TN2012000515A1 (enExample)
TW (1) TWI508722B (enExample)
UA (1) UA109661C2 (enExample)
WO (1) WO2011151080A1 (enExample)
ZA (1) ZA201208767B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177215A1 (en) * 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
EP2311446A1 (en) * 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising Tramadol and Celecoxib in the treatment of pain
US9138425B2 (en) 2013-03-12 2015-09-22 Patheon Inc. Drug delivery system to increase bioavailability
CA2947528C (en) 2014-05-01 2023-09-05 Sun Pharmaceutical Industries Limited Extended release suspension compositions
RU2016147008A (ru) * 2014-05-01 2018-06-04 Сан Фармасьютикал Индастриз Лимитед Жидкие композиции метформина с пролонгированным высвобождением
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
BR112017001968A2 (pt) 2014-07-30 2017-11-21 Sun Pharmaceutical Ind Ltd embalagem de duas câmaras para uma composição farmacêutica líquida oral de múltiplas doses
WO2016046693A1 (en) * 2014-09-25 2016-03-31 Nathwani Sandeep Vinodkumar A co-processed pharmaceutical excipient
CN104276960B (zh) * 2014-09-26 2016-09-28 安徽省逸欣铭医药科技有限公司 盐酸他喷他多和塞来昔布共晶及其组合物和制备方法
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
WO2018031577A1 (en) * 2016-08-09 2018-02-15 Autotelic Llc Fixed dose combination for pain relief without edema
DE102016012746A1 (de) 2016-10-25 2018-04-26 WindplusSonne GmbH Vorprodukte zur Herstellung von porösen, mineralischen Leichtbaumaterialien, Verfahren zur Herstellung von porösen, mineralischen Leichtbaumaterialien und ihre Verwendung
JP2020510625A (ja) * 2016-12-14 2020-04-09 ナンジェネックス ナノテクノロジー インコーポレーテッドＮａｎｇｅｎｅｘ Ｎａｎｏｔｅｃｈｎｏｌｏｇｙ Ｉｎｃｏｒｐｏｒａｔｅｄ セレコキシブを含有する医薬組成物
CN107595792A (zh) * 2017-11-06 2018-01-19 刘丽 一种盐酸他喷他多塞来昔布片剂及其制备方法
CN110101673A (zh) * 2019-05-07 2019-08-09 安徽金太阳生化药业有限公司 一种盐酸曲马多分散片的制备方法
CA3137381A1 (en) * 2019-05-14 2020-11-19 Esteve Pharmaceuticals, S.A. Use of co-crystals of tramadol and celecoxib for treating pain while reducing the abuse liability of tramadol
CN112007024A (zh) * 2019-05-28 2020-12-01 江苏恒瑞医药股份有限公司 艾瑞昔布与曲马多联合在制备治疗疼痛的药物中的用途
SI4337169T1 (sl) * 2021-05-11 2026-05-29 Cingulate Therapeutics LLC Trimodalna tableta s časovno nastavljivim pulzirnim sproščanjem
CN115251264B (zh) * 2022-08-05 2023-11-21 齐鲁工业大学 含桑叶提取物的共结晶粉末功能性饮料及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513924A (en) * 1999-03-01 2001-09-28 Ortho Mcneil Pharm Inc Composition comprising a tramadol material and a selective cox-2 inhibitor drug
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
PT1478366E (pt) * 2002-02-19 2009-03-10 Adcock Ingram Ltd Combinações farmacêuticas de meloxicam, fosfato de codeína e paracetamol
JP2005154334A (ja) * 2003-11-25 2005-06-16 Toa Yakuhin Kk アズレンスルホン酸塩水溶液剤
DE102006044694A1 (de) * 2006-09-22 2008-03-27 Krewel Meuselbach Gmbh Perorale feste Schmerzmittelzubereitung
WO2008085674A1 (en) * 2007-01-04 2008-07-17 Transform Pharmaceuticals, Inc. Pharmaceutical compositions comprising celecoxib co-crystals
CN101254180B (zh) * 2008-03-28 2010-11-10 辽宁正鑫药物研究有限公司 一种内容物为半固体组合物的尼莫地平胶囊剂及制备方法
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs

Also Published As

Publication number Publication date
US20130109659A1 (en) 2013-05-02
EP2575778B1 (en) 2017-01-18
RS55878B1 (sr) 2017-08-31
IL222731A (en) 2016-05-31
DK2575778T3 (en) 2017-04-18
KR20130093015A (ko) 2013-08-21
US8846744B2 (en) 2014-09-30
TW201143760A (en) 2011-12-16
MX2012014087A (es) 2013-02-27
HUE033999T2 (en) 2018-01-29
CA2798090C (en) 2017-02-28
MX351507B (es) 2017-10-18
ECSP13012368A (es) 2013-01-31
EP2392319A1 (en) 2011-12-07
AU2011260608A1 (en) 2012-11-22
CA2798090A1 (en) 2011-12-08
NZ603457A (en) 2014-10-31
IL222731A0 (en) 2012-12-31
SG185385A1 (en) 2012-12-28
SMT201700261T1 (it) 2017-07-18
AR081774A1 (es) 2012-10-17
RU2567843C2 (ru) 2015-11-10
PL2575778T3 (pl) 2017-09-29
PT2575778T (pt) 2017-04-21
CY1118813T1 (el) 2018-03-07
CO6660469A2 (es) 2013-04-30
ES2622192T3 (es) 2017-07-05
MY156859A (en) 2016-04-15
LT2575778T (lt) 2017-04-10
TWI508722B (zh) 2015-11-21
AU2011260608B2 (en) 2015-05-07
SI2575778T1 (sl) 2017-07-31
KR101556700B1 (ko) 2015-10-01
UA109661C2 (uk) 2015-09-25
EP3158994A1 (en) 2017-04-26
JP5800016B2 (ja) 2015-10-28
TN2012000515A1 (en) 2014-04-01
WO2011151080A1 (en) 2011-12-08
RU2012157256A (ru) 2014-07-20
PH12012502171A1 (en) 2016-02-24
JP2013530952A (ja) 2013-08-01
CN102946871A (zh) 2013-02-27
ZA201208767B (en) 2013-07-31
BR112012030704A2 (pt) 2016-09-13
EP2575778A1 (en) 2013-04-10
HRP20170594T1 (hr) 2017-06-16

Similar Documents

Publication Publication Date Title
EP2575778B1 (en) Pharmaceutical compositions of co-crystals of tramadol and coxibs
EP3323413B1 (en) Pharmaceutical composition containing celecoxib and tramadol
KR20200088382A (ko) 방출 제어 제제
TW202038917A (zh) 包含托法替尼或其藥學上可接受的鹽類的延長釋放配方及其製備方法
US9675551B2 (en) Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
US20150359795A1 (en) High drug load pharmaceutical compositions with controllable release rate and production methods thereof
EP2246046A1 (en) Orally disintegrating olanzapine tablet
EP2523657A1 (en) Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
EP3733166A1 (en) Cyclic orally disintegrating tablet
HK1180982A (en) Pharmaceutical compositions of co-crystals of tramadol and coxibs
HK1180982B (en) Pharmaceutical compositions of co-crystals of tramadol and coxibs
EP2934485B1 (en) Tablet composition comprising cinacalcet hydrochloride
RU2603469C2 (ru) Таблетка с контролируемым высвобождением для перорального введения и способ ее приготовления
HK1180981A (en) Pharmaceutical compositions of co-crystals of tramadol and coxibs
Bhavesh et al. INTERNATIONAL RESEARCH JOURNAL OF PHARMACY
BR112012030704B1 (pt) Composição farmacêutica de cocristais e processo para sua produção

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1180981

Country of ref document: HK

CB02 Change of applicant information

Address after: Spain Barcelona

Applicant after: Steven pharmaceutical Limited by Share Ltd

Address before: Spain Barcelona

Applicant before: Enrique Manosas-Barrera/Attorney

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1180981

Country of ref document: HK